Masataka Nishiga

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/323754/publications.pdf

Version: 2024-02-01

26	1,938	566801 15	552369 26
papers	citations	h-index	g-index

26	26	26	3970
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nature Reviews Cardiology, 2020, 17, 543-558.	6.1	999
2	MicroRNA-451 Exacerbates Lipotoxicity in Cardiac Myocytes and High-Fat Diet-Induced Cardiac Hypertrophy in Mice Through Suppression of the LKB1/AMPK Pathway. Circulation Research, 2015, 116, 279-288.	2.0	185
3	MicroRNA-33 regulates sterol regulatory element-binding protein 1 expression in mice. Nature Communications, 2013, 4, 2883.	5.8	183
4	An in Vivo miRNA Delivery System for Restoring Infarcted Myocardium. ACS Nano, 2019, 13, 9880-9894.	7.3	101
5	Genetic Ablation of MicroRNA-33 Attenuates Inflammation and Abdominal Aortic Aneurysm Formation via Several Anti-Inflammatory Pathways. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 2161-2170.	1.1	69
6	MicroRNA-33 Controls Adaptive Fibrotic Response in the Remodeling Heart by Preserving Lipid Raft Cholesterol. Circulation Research, 2017, 120, 835-847.	2.0	55
7	MicroRNA-33b knock-in mice for an intron of sterol regulatory element-binding factor 1 (Srebf1) exhibit reduced HDL-C in vivo. Scientific Reports, 2014, 4, 5312.	1.6	44
8	Cannabinoid receptor 1 antagonist genistein attenuates marijuana-induced vascular inflammation. Cell, 2022, 185, 1676-1693.e23.	13.5	40
9	Prevention of neointimal formation using miRNA-126-containing nanoparticle-conjugated stents in a rabbit model. PLoS ONE, 2017, 12, e0172798.	1.1	28
10	SREBF1 /MicroRNA-33b Axis Exhibits Potent Effect on Unstable Atherosclerotic Plaque Formation In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 2460-2473.	1.1	24
11	Expression Patterns of miRNA-423-5p in the Serum and Pericardial Fluid in Patients Undergoing Cardiac Surgery. PLoS ONE, 2015, 10, e0142904.	1.1	23
12	Therapeutic genome editing in cardiovascular diseases. Advanced Drug Delivery Reviews, 2021, 168, 147-157.	6.6	23
13	Loss of periostin ameliorates adipose tissue inflammation and fibrosis in vivo. Scientific Reports, 2018, 8, 8553.	1.6	22
14	The use of new CRISPR tools in cardiovascular research and medicine. Nature Reviews Cardiology, 2022, 19, 505-521.	6.1	21
15	Identification of Differential Roles of MicroRNAâ€33a and â€33b During Atherosclerosis Progression With Genetically Modified Mice. Journal of the American Heart Association, 2019, 8, e012609.	1.6	17
16	Dynamic changes of serum microRNAâ€122â€5p through therapeutic courses indicates amelioration of acute liver injury accompanied by acute cardiac decompensation. ESC Heart Failure, 2017, 4, 112-121.	1.4	16
17	microRNA-33 maintains adaptive thermogenesis via enhanced sympathetic nerve activity. Nature Communications, 2021, 12, 843.	5.8	14
18	Deciphering pathogenicity of variants of uncertain significance with CRISPR-edited iPSCs. Trends in Genetics, 2021, 37, 1109-1123.	2.9	14

#	Article	IF	Citations
19	CRISPRi/a Screening with Human iPSCs. Methods in Molecular Biology, 2021, 2320, 261-281.	0.4	13
20	MicroRNA 33 Regulates the Population of Peripheral Inflammatory Ly6C^{high} Monocytes through Dual Pathways. Molecular and Cellular Biology, 2018, 38, .	1.1	11
21	Induced pluripotent stem cells as a biopharmaceutical factory for extracellular vesicles. European Heart Journal, 2018, 39, 1848-1850.	1.0	11
22	Hepatokine Î±1-Microglobulin Signaling Exacerbates Inflammation and Disturbs Fibrotic Repair in Mouse Myocardial Infarction. Scientific Reports, 2018, 8, 16749.	1.6	9
23	MiR-33a is a therapeutic target in SPG4-related hereditary spastic paraplegia human neurons. Clinical Science, 2019, 133, 583-595.	1.8	7
24	Ferroptosis of Pacemaker Cells in COVID-19. Circulation Research, 2022, 130, 978-980.	2.0	4
25	Lionheart LincRNA alleviates cardiac systolic dysfunction under pressure overload. Communications Biology, 2020, 3, 434.	2.0	3
26	Macrophages: Potential Therapeutic Target of Myocardial Injury in COVID-19. Circulation Research, 2021, 129, 47-49.	2.0	2